Preliminary research suggests that a drug typically used to kickstart the immune system may help cancer patients who receive stem cell transplants and then develop a potentially deadly side effect. The drug appears to work by preventing the donor’s immune system cells from overreacting to their new home and causing systemic inflammation.
